文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response.

作者信息

Floberg John M, Kyriakopoulos Christos E, Cho Steve Y

机构信息

Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Division of Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

出版信息

Adv Radiat Oncol. 2025 May 10;10(8):101805. doi: 10.1016/j.adro.2025.101805. eCollection 2025 Aug.

DOI:10.1016/j.adro.2025.101805
PMID:40697966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12282200/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ee/12282200/10a7aeaacf30/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ee/12282200/0f5dc703daa6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ee/12282200/187446d18915/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ee/12282200/10a7aeaacf30/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ee/12282200/0f5dc703daa6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ee/12282200/187446d18915/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14ee/12282200/10a7aeaacf30/gr3.jpg

相似文献

[1]
Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response.

Adv Radiat Oncol. 2025-5-10

[2]
Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.

J Urol. 2021-2

[3]
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Cochrane Database Syst Rev. 2002

[4]
Sensitivity, Specificity, and Predictors of Positive Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

Eur Urol. 2016-6-28

[5]
The Safety and Efficacy of Targeted Alpha Therapy, Ac-225 Prostate-Specific Membrane Antigen, in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Prostate. 2025-5

[6]
[Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.

Eur J Clin Invest. 2025-5

[7]
Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review.

Eur Urol Oncol. 2024-12

[8]
Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.

ACS Appl Mater Interfaces. 2021-11-24

[9]
Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.

Eur J Nucl Med Mol Imaging. 2017-12-16

[10]
Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.

Eur J Nucl Med Mol Imaging. 2025-7-24

本文引用的文献

[1]
Overall survival with [Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.

Lancet Oncol. 2024-1

[2]
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.

Lancet Oncol. 2022-11

[3]
Development and validation of a longitudinal soft-tissue metastatic lesion matching algorithm.

Phys Med Biol. 2021-7-30

[4]
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med. 2021-9-16

[5]
Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma.

Radiol Artif Intell. 2020-9-2

[6]
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.

Target Oncol. 2021-5

[7]
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Lancet. 2021-2-27

[8]
Exploring Spatial-Temporal Changes in F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.

J Clin Oncol. 2020-11-1

[9]
Quantitative Test-Retest Measurement of Ga-PSMA-HBED-CC in Tumor and Normal Tissue.

J Nucl Med. 2019-12-5

[10]
A statistically optimized regional thresholding method (SORT) for bone lesion detection in F-NaF PET/CT imaging.

Phys Med Biol. 2018-11-20

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索